To avoid these off-target impacts, several other less potent SIRT1 activators have been identified, such as piceatannol, which has been used in many preclinical trials and shows potential to prevent or impede growth of different cancers (Banik et al., 2020). The gene discussed is SIRT1; the disease is cancer.